Table 3.
Subgroup Analysis of Tuberculosis Outcomes and Randomized Treatment Duration by Human Immunodeficiency Virus Status
| Children With HIV | Children Not Diagnosed With HIV | ||||
|---|---|---|---|---|---|
| Subgroup parameters assessed | 4 Months | 6 Months | 4 Months | 6 Months | Total |
| Total randomized | 65 | 62 | 537 | 540 | 1204 |
| Unassessablea | 6 | 8 | 24 | 21 | 59 |
| Did not reach week 16 | 4 | 5 | 11 | 11 | 31 |
| Favorable | 55 (93%) | 48 (89%) | 501 (98%) | 507 (98%) | 1111 (97%) |
| Unfavorable | 4 (7%) | 6 (11%) | 12 (2%) | 12 (2%) | 34 (3%) |
| Total assessable | 59 | 54 | 513 | 519 | 1145 |
| Difference from control in unfavorable rate | − 4.3% | … | 0.03% | … | … |
| 95% confidence interval | (−14.9 to 6.2) | … | (−1.8 to 1.9) | … | … |
Test for interaction: P value = .42. Test for interaction compares the effects (risk difference) of treatment duration on tuberculosis (TB) outcomes, comparing children with HIV and children not diagnosed with HIV.
Abbreviation: HIV, human immunodeficiency virus.
aReasons for unassessable include not reaching week 16 and late exclusions for drug-resistant TB.